Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 15;20(4):791-8.
doi: 10.1158/1078-0432.CCR-12-3601. Epub 2013 Dec 4.

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit

Elahe A Mostaghel  1 , Stephen R Plymate, Bruce Montgomery
Affiliations

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit

Elahe A Mostaghel et al. Clin Cancer Res. .

Abstract

Androgen receptor signaling is critical in the development and progression of prostate cancer, leading to intensive efforts to elucidate all potential points of inflection for therapeutic intervention. These efforts have revealed new mechanisms of resistance and raise the possibility that known mechanisms may become even more relevant in the context of effective androgen receptor suppression. These mechanisms include tumoral appropriation of alternative androgen sources, alterations in androgen receptor expression, androgen receptor mutations, truncated androgen receptor variants, alterations and cross-talk in recruitment of cofactors to androgen receptor binding sites in the genome, and androgen receptor-driven oncogenic gene fusions. New agents such as enzalutamide, EPI-001, androgen receptor-specific peptidomimetics, novel HSP90 inhibitors, and PARP inhibitors, as well as new approaches to cotargeting the androgen receptor pathway, point to the potential for more complete and durable control of androgen receptor-mediated growth.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure A - Schematic of the full-length androgen receptor (a) and exon structure of major splice variants (ARV7 (b) and ARV567 (c)). Domains of AR include the amino (N) terminal domain, the DNA binding domain (DBD), the hinge region (HR), and the carboxy (C) terminal ligand-binding domain (LBD). Mutations which occur in specific regions are indicated. Adapted from Green and colleagues (68) with permission from Elsevier. Figure 1B - ADVANCES: Inhibition of AR ligand production: Inhibition of CYP17A by Abiraterone, Orteronel, Galeterone, VT474, or CFG920 suppresses testicular, adrenal and tumoral androgen synthesis. Galeterone can suppress CYP17A, antagonize androgens and reduce AR levels. Abiraterone at high doses can inhibit AR and HSD3B. AR degradation: AR can be destabilized through inhibition of HSP90 binding. AR-cofactor association: Peptidomimetics (e.g. D2) can disrupt AR interaction with cofactors, decreasing AR driven gene transcription. AR antagonism: Enzalutamide and ARN509 block ligand/receptor interactions at the LBD, reduce AR-DNA association and AR nuclear accumulation. EPI-001 blocks AR NTD-coactivator association and nuclear accumulation, and is active against truncated AR variants lacking the C terminal domain (CTD). Adapted from Knudsen K, et al (69)
Figure 1
Figure 1
Figure A - Schematic of the full-length androgen receptor (a) and exon structure of major splice variants (ARV7 (b) and ARV567 (c)). Domains of AR include the amino (N) terminal domain, the DNA binding domain (DBD), the hinge region (HR), and the carboxy (C) terminal ligand-binding domain (LBD). Mutations which occur in specific regions are indicated. Adapted from Green and colleagues (68) with permission from Elsevier. Figure 1B - ADVANCES: Inhibition of AR ligand production: Inhibition of CYP17A by Abiraterone, Orteronel, Galeterone, VT474, or CFG920 suppresses testicular, adrenal and tumoral androgen synthesis. Galeterone can suppress CYP17A, antagonize androgens and reduce AR levels. Abiraterone at high doses can inhibit AR and HSD3B. AR degradation: AR can be destabilized through inhibition of HSP90 binding. AR-cofactor association: Peptidomimetics (e.g. D2) can disrupt AR interaction with cofactors, decreasing AR driven gene transcription. AR antagonism: Enzalutamide and ARN509 block ligand/receptor interactions at the LBD, reduce AR-DNA association and AR nuclear accumulation. EPI-001 blocks AR NTD-coactivator association and nuclear accumulation, and is active against truncated AR variants lacking the C terminal domain (CTD). Adapted from Knudsen K, et al (69)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63:11–30. - PubMed
    1. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 1998;273:20213–22. - PubMed
    1. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138:245–56. - PMC - PubMed
    1. Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006;66:7783–92. - PubMed
    1. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457–71. - PMC - PubMed

Publication types

MeSH terms